Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease

Area of Science:

• Respiratory Medicine
• Pharmacology

Background:

• Chronic bronchitis and COPD patients experience recurrent exacerbations, increasing sputum volume and purulence.
• Exacerbations incur significant personal and healthcare costs, highlighting the need for effective therapies.
• Global variations exist in mucolytic prescribing, influenced by perceived efficacy.

Purpose of the Study:

• To evaluate the efficacy of oral mucolytics in adults with stable chronic bronchitis or COPD.
• To assess the impact of oral mucolytics on exacerbation frequency and disability.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials.
• Included trials compared oral mucolytic therapy with placebo for at least two months.
• Excluded studies involving patients with asthma or cystic fibrosis.

Main Results:

• Oral mucolytics significantly reduced the number of exacerbations per patient by 20% compared to placebo.
• A significant reduction in disability days was observed with mucolytic treatment.
• Patients receiving mucolytics had a higher likelihood of remaining exacerbation-free.

Conclusions:

• Oral mucolytics are associated with a modest reduction in acute exacerbations and disability days in COPD and chronic bronchitis patients.
• Benefits may be more pronounced in patients with frequent exacerbations or hospital admissions.
• Consideration for mucolytic use, especially during winter, is recommended for moderate to severe COPD patients not prescribed inhaled corticosteroids.